FDA Grants Lupuzor Fast Track Status

An even more positive update on the novel drug in development, Lupozor; per request from drug developer ImmuPharma, the U.S. Food and Drug Administration granted Lupuzor Fast Track Designation. “The fast track programs of the FDA are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs (fast track products).”

Full story